Business, energy, technology, markets and global industry news from Business News Today

bispecific antibody

PharmaDeviceNews bispecific antibody
Representative image: Antengene’s ATG-106 licensing deal highlights growing biotech interest in CDH6 x CD3 T cell engagers for solid tumor immunotherapy.
Pharma & Biotech

Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs

Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.

Read More
Representative image: An oncologist reviews lung scan images in a modern cancer care setting, reflecting Amgen’s EU approval for Imdylltra in relapsed extensive-stage small cell lung cancer.
Pharma & Biotech

Why Amgen’s Imdylltra EU approval could reshape second-line small cell lung cancer treatment

Find out how Amgen’s Imdylltra EU approval could change relapsed small cell lung cancer treatment across Europe.

Read More
Representative image of an oncologist reviewing lung cancer scans in a modern treatment room, reflecting Amgen’s European approval for Imdylltra and the growing shift toward bispecific antibody therapies for extensive-stage small cell lung cancer.
Pharma & Biotech

Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?

Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Pharma & Biotech

FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity

Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.

Read More
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Pharma & Biotech

Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update

Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.

Read More
Pharma & Biotech

What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition

NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.

Read More
Pharma & Biotech

Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition

Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.

Read More
B Cell Llama platform positions MindWalk for partnership deals in bispecific drug discovery
Pharma & Biotech

MindWalk adds VHH capability as nanobodies gain ground in CAR-T and multispecific design

MindWalk launches B Cell Llama, a VHH nanobody platform for bispecific drug design. Peer-reviewed data raises key questions about function, immunogenicity, and AI.

Read More